Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

BESPONSA (inotuzumab ozogamicin) for the Treatment of Acute Lymphoblastic Leukaemia

Drug Name

BESPONSA® (inotuzumab ozogamicin)

Developer

Pfizer

Therapy Class

Monoclonal antibody

Current Indication

Acute lymphoblastic leukaemia

Market Sector

Oncology

Development Status

Approved in the US and Europe
Expand

Go Top